Choosing whether to lease or buy major bioprocessing equipment is one of the most consequential financial decisions a lab manager makes. For bioreactors, chromatography skids, and filtration systems priced from $200,000 to several million dollars, the acquisition model directly affects capital availability, balance sheet flexibility, and operational agility. Neither approach is universally superior; the decision turns on utilization rates, development stage, available capital, and technology lifecycle.

Quick Take

• Purchasing offers lower lifetime cost and full depreciation benefits, but only when utilization is consistently high and equipment lifespan exceeds the amortization period
• Leasing preserves capital for consumables, staffing, and operational spend, and provides a structured upgrade path as technology evolves
• Under ASC 842, most equipment leases must now appear on the balance sheet, so the accounting advantage of leasing is more nuanced than it once appeared
• Utilization rate is the single most predictive variable: equipment running below 60–70% of capacity rarely justifies outright purchase
• Development-stage and contract development and manufacturing organization (CDMO) facilities typically benefit more from leasing; commercial-scale, single-product facilities typically benefit more from purchase

Why acquisition model matters more in bioprocessing than in general lab settings

Bioprocessing equipment carries a financial risk profile unlike most other laboratory instrumentation. A bioreactor or tangential flow filtration (TFF) system is not only expensive to acquire, qualify, maintain, and decommission. Every piece of good manufacturing practice (GMP)-critical equipment must undergo installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ) before it can support regulated manufacturing, and those qualification costs are incurred whether the bioprocessing equipment is leased or purchased outright.

This makes the upfront acquisition decision high-stakes: qualification expense is a sunk cost from day one. At development scale, equipment requirements change rapidly as processes advance from process development through clinical manufacturing toward commercial production. A 50L single-use bioreactor that is perfectly sized for a Phase I program may be obsolete within 18 months if the program advances.

Compendium

Chromatographic Selectivity for Trace Nitrosamines and Intact Biopharmaceuticals

An evaluation of the column geometries, stationary phase interactions, and mobile phase conditions that resolve co-elution at regulatory limits

Read Compendium

Purchasing that system outright at clinical scale creates a disposal or redeployment problem at precisely the point when capital is most constrained. The compliance burden attaches regardless of ownership structure. A leased bioreactor is subject to the same IQ/OQ/PQ regime as a purchased one, and those qualification costs land on the lessee just as squarely as on the owner.

The financial mechanics: CapEx versus OpEx and what each actually costs

Purchasing bioprocessing equipment is a capital expenditure (CapEx) event and, for major systems, one of the largest single line items a lab manager will authorize. The full acquisition cost (including freight, installation, and qualification) is capitalized on the balance sheet and depreciated over the useful life of the asset, typically five to ten years under US Generally Accepted Accounting Principles (GAAP). The IRS depreciation framework (Topic 704) and Section 179 expensing elections allow accelerated write-downs in the year of purchase, delivering meaningful tax benefits for organizations with sufficient taxable income.

Leasing converts a large CapEx event into a predictable operating expenditure (OpEx) stream of monthly or quarterly payments flowing through the income statement rather than the balance sheet. This is strategically valuable for facilities with capital constraints or organizations whose investors scrutinize CapEx authorizations closely. For bioprocessing equipment leasing, a $1.2 million bioreactor system can often be structured as a 48-month operating lease at approximately $27,000–$32,000 per month, depending on the lessor, residual value assumptions, and the borrower's credit profile.

The important accounting caveat is ASC 842 (Accounting Standards Codification Topic 842), issued by the Financial Accounting Standards Board (FASB) in 2016 and effective for US public companies from fiscal years beginning after December 15, 2018. It eliminated the ability to keep most operating lease obligations off the balance sheet. Under ASC 842, operating leases with terms exceeding 12 months must be recorded as right-of-use (ROU) assets with corresponding lease liabilities.

The practical effect is that leasing no longer provides a clean balance sheet advantage, though it still preserves cash and maintains OpEx flexibility. Finance leases, structured to transfer substantially all the risks and rewards of ownership, are treated similarly to financed purchases under ASC 842.

How utilization rate drives the decision

Equipment utilization is the most underweighted variable in lease-versus-buy analyses. A bioreactor running at 85% of capacity five days a week across a ten-year lifespan will almost always be cheaper to own than to lease, as the total ownership cost is spread across enough productive hours that the per-run economics favor purchase. The same bioreactor running at 40% capacity, typical at early development stage or in a multiproduct facility with shifting priorities, represents a very different calculation.

Lab Quality Management Certificate

The Lab Quality Management certificate is more than training—it’s a professional advantage.

Gain critical skills and IACET-approved CEUs that make a measurable difference.

A reliable threshold used by many facility planners is the 60–70% utilization floor. Below that level, fixed ownership costs, including depreciation, preventive maintenance contracts, calibration, facility space, and qualification upkeep, are spread across too few productive runs to justify the capital commitment. For bioprocessing equipment leasing decisions, this threshold is a practical starting point, not a hard rule, and should be adjusted based on the cost structure of the equipment category.

A useful approach is the comparative TCO model. Calculate the full ownership cost over a defined period (acquisition, installation, qualification, annual maintenance, and calibration) then divide by the expected number of operational hours. Compare that figure to the effective per-hour cost of a lease at projected utilization.

This methodology, applied to in vitro laboratory equipment by Mamalougkas and Tzavaras (2023), provides a replicable framework for identifying the break-even utilization point at which bioprocessing equipment leasing stops being advantageous. Running the model at both optimistic and pessimistic scenarios before committing is the financially rigorous standard.

Interested in life sciences?

Register for a FREE Lab Manager account to subscribe to our Life Sciences Newsletter.

Subscribe for Free

Development stage and organizational context as decision drivers

The development stage of a bioprocessing program is frequently the most decisive contextual variable. Early-stage facilities running process development, Phase I clinical manufacturing, or feasibility studies typically benefit from leasing. Process requirements are likely to change before the next scale-up, equipment needs will shift as programs advance or fail, and capital is most constrained precisely when it is needed most.

As a program advances toward Phase III and commercial manufacturing, the economics shift. Process parameters are locked, equipment specifications are fixed, and the run schedule is reliably predictable. A dedicated GMP facility supporting a single approved product is a strong candidate for outright purchase; a CDMO running multiple programs with varying volume demands may be better served by a lease-heavy strategy.

The GMP compliance obligations that attach to commercially manufactured products add weight to ownership, as a facility's equipment qualification records become part of the regulatory submission package, making continuity of ownership operationally valuable.

Organizational structure also matters. Academic core facilities, government laboratories, and early-stage startups often face restrictions on large capital commitments or governance thresholds that make large equipment purchases hard to authorize. Leasing allows these organizations to access equipment their approval structures would not otherwise support.

Conversely, large biopharma organizations with strong balance sheets and predictable manufacturing schedules often prefer ownership for its lower lifetime cost and direct control over maintenance and qualification cycles. The lease-versus-buy analysis typically runs in parallel with the single-use versus stainless steel infrastructure decision, and both hinge on the same CapEx-versus-flexibility calculus and are usually resolved together when a new bioprocessing facility is commissioned.

Structuring a lease: what to negotiate before signing

Not all equipment leases are equivalent, and the terms negotiated at signing determine the practical value of the arrangement. Several provisions deserve particular attention when leasing GMP-critical bioprocessing equipment.

Technology refresh clauses allow lessees to upgrade to a newer model at a defined point, typically at the midpoint or end of the initial term, without penalty. For rapidly evolving categories like single-use bioreactors and process analytical technology (PAT) sensors, this provision can be the most strategically valuable element of a bioprocessing equipment lease.

Qualification and validation responsibility should be explicitly addressed. Because IQ/OQ/PQ costs are borne by the user regardless of ownership, the lease should specify who bears the cost of requalification if lessor maintenance constitutes a change requiring revalidation, which is a frequent friction point in GMP environments.

End-of-term options (purchase at fair market value, lease extension, or return) should be reviewed in the context of the facility's anticipated program pipeline. Whether preventive maintenance and calibration are bundled into the lease payment also has significant implications for compliance documentation; a bundled arrangement can simplify the record-keeping obligations that accompany any bioprocessing equipment service agreement.

Scenarios where each approach wins

Neither leasing nor buying is the universal answer. The following framework maps common bioprocessing equipment leasing and purchasing scenarios to the acquisition model most likely to deliver the best outcome.

Purchase is likely the better choice when:

• The facility operates a single approved product at commercial scale with consistently high utilization
• The equipment category is mature, with minimal technology evolution expected over a five- to ten-year horizon
• The organization has sufficient taxable income to benefit from accelerated depreciation under Section 179
• The program timeline is long enough that the TCO break-even point will be reached well before end of useful life

Once the decision to purchase is made, the full procurement lifecycle, from RFP through installation qualification introduces its own financial and operational variables that affect total cost.

Leasing is likely the better choice when:

• The facility is in process development, Phase I, or Phase II and equipment specifications are likely to change
• Utilization is projected below 60–70% of capacity due to program mix or schedule variability
• Capital preservation is a priority: for reagents, consumables, staffing, or pipeline investment
• The equipment category is evolving rapidly and technology refresh is strategically valuable
• CapEx approval processes would delay procurement beyond operationally acceptable timelines

Conclusion: matching acquisition model to operational reality

The lease-versus-buy decision for bioprocessing equipment requires matching the acquisition model to the operational reality of a facility. High-utilization, commercial-scale, single-program facilities almost always benefit from ownership over a defined horizon. Development-stage, multiproduct, and CDMO facilities often benefit from the flexibility and capital efficiency of leasing, particularly when equipment categories are evolving or program pipelines carry meaningful uncertainty.

The financially rigorous approach is to calculate the true TCO for both options at projected utilization rates, apply the correct accounting treatment under ASC 842, and stress-test the analysis against optimistic and pessimistic scenarios. As the bioprocessing lab operations guide makes clear, equipment acquisition decisions are inseparable from facility strategy and belong at the start of the planning process.

References

1. Mamalougkas, B.D., & Tzavaras, E.P. (2023). Total cost of ownership as an effective method of calculating the total cost of in vitro laboratory equipment. Proceedings of the 6th International Conference on Research in Business, Management and Finance. https://doi.org/10.33422/6th.icrbmf.2023.09.103
2. Financial Accounting Standards Board. (2016). Accounting Standards Update No. 2016-02: Leases (Topic 842). FASB. https://www.fasb.org/project/leases
3. Internal Revenue Service. (2024). Topic no. 704: Depreciation. IRS. https://www.irs.gov/taxtopics/tc704

This content includes text that has been generated with the assistance of AI. For more information, view Lab Manager's AI use policy.